Service utilization and costs of first-onset schizophrenia in two widely differing health service areas in North-East Spain

Acta Psychiatrica Scandinavica

Volumn 100, Issue 5, 1999, Pages 335-343

  Salvador Carulla, L ^a   Haro, J M ^b   Cabases J ^c   Madoz, V ^d   Sacristan J A ^e   Vazquez Barquero J L ^f  

^a UNIVERSITY OF CÁDIZ   (Spain)

^b PARC SANITARI SANT JOAN DE DÉU   (Spain)

^c PUBLIC UNIVERSITY OF NAVARRE   (Spain)

^d Argibide Foundation   (Spain)

^e ELI LILLY AND COMPANY   (Spain)

^f UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Costs; Equity; Schizophrenia; Service; Utilization

Indexed keywords

ARTICLE; CLINICAL FEATURE; COMMUNITY CARE; CONTROLLED STUDY; COST OF ILLNESS; DEMOGRAPHY; DISABILITY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH PROGRAM; MENTAL HEALTH; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL ASPECT; SPAIN;

EID: 0032722256     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1999.tb10876.x     Document Type: Article

References (31)

1. 1. Wyatt RJ, Henter I, Leary MC, Taylor E. An economic evaluation of schizophrenia 1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:196-205.
2. 2. Rice DP, Miller LS. The economic burden of schizophrenia. In: Moscarelli M, Rupp A, Sartorius N, ed. Handbook of mental health economics and heahh policies. Vol. I. Schizophrenia. Chichester: John Wiley & Sons, 1996;321-334.
3. 3. Goldberg D. Cost-effectiveness in the treatment of patients with schizophrenia. Acta Psychiatr Scand 1994;89(Suppl. 382):89-92.
4. 4. Kavanagh S, Opit L, Knapp M, Beecham J. Schizophrenia: shifting the balance of care. Soc Psychiatry Psychiatr Epidemiol 1995;30:196-205.
5. 5. Smith K, Shah A, Wright K et al. The prevalence and costs of psychiatric disorders and learning disabilities. Br J Psychiatry 1995;166:9-18.
6. 6. Lund P. Calculation of the costs of schizophrenia in Denmark. Paper presented at the Third Workshop on Costs and Assessment in Psychiatry, ARCAP, Venice, 28-30 October 1994.
7. 7. Meerding WJ, Bonneux L, Polder JJ, Koopmanschap MA, van der Maas PJ. Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. Br Med J 1998;317:111-115.
8. 8. Andrews G, Hall W, Goldstein G, Lapsley H, Bartels R, Silove D. The economic costs of schizophrenia. Implications for public policy. Arch Gen Psychiatry 1985;42:537-543.
9. 9. Langley-Hawthorne C. Modeling the lifetime costs of treating schizophrenia in Australia. Clin Ther 1997; 19:1470-1495.
10. 10. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994;165(Suppl. 25):18-21.
11. 11. Wiersma D, Giel R, De Jong A, Sloof CJ. Schizophrenia: results of a cohort study with respect to cost-accounting problems of patterns of mental health care in relation to course of illness. In: Schwefel D, Zöllner H, Potthoff P, ed. Costs and effects of managing chronic psychotic patients. Berlin: Springer-Verlag, 1988;115-125.
12. 12. Moscarelli MS, Capri S, Neri L. Cost evaluation of chronic schizophrenic patients during the first three years after the first contact. Schizophr Bull 1991;17(Suppl. 3):421-426.
13. 13. Ozámiz JA, Cabasés JM. Economic analysis of different patterns of psychiatric treatment and management of chronic psychotic patients in the Basque Country. In: Schwefel D, Zöllner H, Potthoff P, ed. Costs and effects of managing chronic psychotic patients. Berlin: Springer-Verlag, 1988;97-105.
14. 14. Johnson S, Salvador-Carulla L and the EPCAT Group. Description and classification of mental health services: a European perspective. Eur Psychiatry 1998;13:333-341.
15. 15. Salvador-Carulla L, Atienza C, Romero C. Use of the EPCAT model of care for standard description of psychiatric services: the experience in Spain. In: Guimón J, Sartorius N, ed. Manage or perish: the challenges of managed mental health care in Europe. New York: Plenum, 1999;in press.
16. 16. Sonnenberg FA, Roberts MS, Tsevat J, Wong JB, Barry M, Kent DL. Toward a peer review process for medical decision analysis models. Med Care 1994; 32(Suppl.7):JS52-JS64.
17. 17. Benach J, Borrell C, Chamizo H. Desigualdades sociales en mortalidad en áreas pequeñas en España. In: Catalá F, De Manuel E, ed. Informe SESPAS, 1998: La Salud Pública y el futuro del estado del bienestar. Granada: Escuela Andaluza de Salud Pública, 1998:141-176.
18. 18. Salvador-Carulla L. Mental health services in Spain. In: Moscarelli M, Rupp A, Sartorius YN, ed. The handbook of mental health economics and health policies. Vol 1. Schizophrenia. Chichester: John Wiley & Sons, 1996;461-464.
19. 19. Gobierno de Navarra. Coste de salud mental: Año 1994. Pamplona: Servicio de Administratión y Servicios Generales, Departamento de Salud. Gobierno de Navarra 1995.
20. 20. González de Chavéz M. Posibles indicadores para el análisis de las reformas psiquiátricas. In: Aparicio V, ed. Evaluación de Servicios de Salud Mental. Madrid: Asociación Española de Neuropsiquiatría, 1993;53-94.
21. 21. Vázquez-Barquero JL, Cuesta MJ, De la Varga M, Herrera S, Gaite L, Arenal A. The Cantabria first-episode schizophrenia study: a summary of general findings. Acta Psychiatr Scand 1995;91:156-162.
22. 22. Bromet EJ, Dew MA, Eaton W. Epidemiology of psychosis with special reference to schizophrenia. In: Tsuang MT, Tohen M, Zahner GE, ed. Textbook of psychiatric epidemiology. New York: Wiley-Liss, 1995;283-300.
23. 23. Prudo R, Blum HM. Five-year outcome and prognosis in schizophrenia. Br J Psychiatry 1987;150:345-354.
24. 24. Goldman HH, Skodol AE, Lave TR. Revising Axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992;149:1148-1156.
25. 25. Daradkeh TK, Saad A. The reliability and validity of the proposed Axis V (disabilities) of ICD-10. Br J Psychiatry 1994;165:683-685.
26. 26. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacology 1998;8:55-66.
27. 27. World Health Organization. Psychiatric Disability Assessment Schedule (WHO/DAS). Geneva: World Health Organization, 1988.
28. 28. Netten A, Beecham J (ed.). Costing community care. Theory and practice. Aldershot: Ashgate, 1993.
29. 29. Mauskopf JA, Paul JE, Grant DM. The role of cost-consequence analysis in health-care decision-making. Pharmacoeconomics 1998;13:277-288.
30. 30. Häfner H, Maurer K, Löffler W, Riecher-Rössler A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993;162:80-86.
31. 31. Hallam A, Knapp M, Beecham J, Fenyo A. Eight years of psychiatric reprovision: an economic evaluation. In: Knapp M, ed. The economic evaluation of mental health care. Aldershot: Arena, 1995;103-124.